Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 7

1.

Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

Jubb AM, Harris AL.

Lancet Oncol. 2010 Dec;11(12):1172-83. doi: 10.1016/S1470-2045(10)70232-1. Review.

PMID:
21126687
2.

VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.

Nagengast WB, Lub-de Hooge MN, Oosting SF, den Dunnen WF, Warnders FJ, Brouwers AH, de Jong JR, Price PM, Hollema H, Hospers GA, Elsinga PH, Hesselink JW, Gietema JA, de Vries EG.

Cancer Res. 2011 Jan 1;71(1):143-53. doi: 10.1158/0008-5472.CAN-10-1088. Epub 2010 Nov 17.

3.

Targeted therapies of cancer: angiogenesis inhibition seems not enough.

Roodink I, Leenders WP.

Cancer Lett. 2010 Dec 18;299(1):1-10. doi: 10.1016/j.canlet.2010.09.004. Review.

PMID:
20889254
4.

Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.

Niu G, Chen X.

Curr Drug Targets. 2010 Aug;11(8):1000-17. Review.

5.

Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.

Kourlas H, Abrams P.

Clin Ther. 2007 Sep;29(9):1850-61. Review.

PMID:
18035187
6.

In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.

Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN.

J Nucl Med. 2007 Aug;48(8):1313-9. Epub 2007 Jul 13.

7.

Supplemental Content

Support Center